Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.47 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16880253 | 0.93 | ALDH1A1 (0.63) | ALDH1A1MAPK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL305618 | 0.80 | ALDH1A1 (1.00) | ALDH1A1MAPK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL7173471 | 0.73 | ALDH1A1 (0.64) | ALDH1A1MAPK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL13125914 | 0.71 | ALDH1A1 (0.78) | ALDH1A1MAPK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL5253114 | 0.70 | ALDH1A1 (0.55) | ALDH1A1MAPK1ATAD2MAPT | |
| SCHEMBL170013 | 0.68 | ALDH1A1 (1.00) | ALDH1A1MAPK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL691842 | 0.68 | ALDH1A1 (0.92) | ALDH1A1MAPK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL692363 | 0.68 | ALDH1A1 (0.56) | ALDH1A1MAPK1ATAD2MAPT | |
| SCHEMBL4946524 | 0.67 | ALDH1A1 (0.50) | ALDH1A1MAPK1PIK3CDPIK3CAPIK3CB | |
| Bromide SCHEMBL3450128 | 0.67 | ALDH1A1 (0.96) | ALDH1A1MAPK1PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9243000-B2 | Thia-triaza-indacenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9243000-B2 | Thia-triaza-indacenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| EP-2421872-B1 | THIA-TRIAZA-AS-INDACENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| WO-2010122091-A1 | THIA-TRIAZA-AS-INDACENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | CCNA1, MKI67, CCNT1 | ALDH1A1 51/4885MAPK1 1145/4885PIK3CD 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.